Pakistan Research Repository

PHARMACOKINETICS OF A NEW QUINOLONE ANTIBIOTIC TOSUFLOXACIN TOSYLATE IN THE PAKISTAN POPULATION

Sial, Ali Akbar (1996) PHARMACOKINETICS OF A NEW QUINOLONE ANTIBIOTIC TOSUFLOXACIN TOSYLATE IN THE PAKISTAN POPULATION. PhD thesis, University of Karachi, Karachi.

[img]HTML
10Kb

Abstract

Tosufloxacin is a new pyridonecarboxylic acid (quinolone) antibiotic with a broad spectrum of antibacterial activity recently developed by Toyama Chemicals Co., Japan, which shows dose dependence and genetic variability in its pharmacokinetics. Several Asian countries are the first ones to market tosufloxacin and thus assessment of its pharmacokinetics is needed in these population. Therefore, a single dose, cross-over comparative study of two brands of tosufloxacin tosylate 150mg tablets was conducted in healthy adult volunteers, as per protocols meeting US FDA guidelines to evaluate pharmacokinetic and bioavailability parameters in Pakistani population Two tossulfloxacin brands were administered orally separated by one week, being given in a dose of 150 mg. The pharmacokinetics were studied in 14 subjects. Serum samples were collected up to 12 hours and were analyzed as per newly developed microbiological method. Serum concentrations calculated. The absorption rates were much faster i.e., the peak levels of tosufloxacin were 0.72 µg/mL, achieved within four hours. The half-life of about 3.33 hours was in agreement with literature values at all dose levels (300-900 mg). Total body clearance of 25 – 153 liters/hr., distribution volume of 100.04 – 475.00 liters and the AUC was 0.98 – 5.95 µg/mL hr. with 100% relative bioavailability between brands. All of these parameters indicate non-linear kinetics at this dose Several new methods were used for statistical analysis, including Bayesian theory, the use of confidence intervals and the two one sided test procedures along with ANOVA.The results of the present study indicated no significant difference in the peak concentration (p>0.05) and the area under the cover (p>0.05) of two brands of tosufloxacin 150mg tablets The partial-area method for bioequivalence assessment was also applied and it was suggested that due to the faster absorption rate and shorter half-life, this method can not be effectively utilized for tosufloxacin bioequivalence study From these pharmacokinetic and statistical evaluations, we concluded no significant difference between two brands of tosufloxacin studied and thus both the products are said to be bioequivalent in Pakistani population. However, pharmacokinetics at high dose was non-linear

Item Type:Thesis (PhD)
Uncontrolled Keywords:quinolone antibiotic, tosufloxacin tosylate, pyridonecarboxylic acid
Subjects:Biological & Medical Sciences (c) > Medical Sciences (c2) > Pharmacy(c2.5)
ID Code:1293
Deposited By:Mr. Muhammad Asif
Deposited On:27 Jan 2007
Last Modified:04 Oct 2007 21:05

Repository Staff Only: item control page